title: Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation.
abstract: For many patients with symptomatic atrial fibrillation, cardioversion is performed to restore sinus rhythm and relieve symptoms. Cardioversion carries a distinct risk for thromboembolism which has been described to be in the order of magnitude of 1 to 3 %. For almost five decades, vitamin K antagonist therapy has been the mainstay of therapy to prevent thromboembolism around the time of cardioversion although not a single prospective trial has formally established its efficacy and safety. Currently, three new direct oral anticoagulants are approved for stroke prevention in patients with non-valvular atrial fibrillation. For all three, there are data regarding its usefulness during the time of electrical or pharmacological cardioversion. Due to the ease of handling, their efficacy regarding stroke prevention, and their safety with respect to bleeding complications, the new direct oral anticoagulants are endorsed as the preferred therapy over vitamin K antagonists for stroke prevention in non-valvular atrial fibrillation including the clinical setting of elective cardioversion.
authors.affiliation: Department of Cardiology, Division of Clinical Electrophysiology, JW Goethe University, Frankfurt, Germany.
authors.forename: Philipp
authors.initials: P
authors.lastname: Bushoven
authors.affiliation: Department of Cardiology, Division of Clinical Electrophysiology, JW Goethe University, Frankfurt, Germany.
authors.forename: Sven
authors.initials: S
authors.lastname: Linzbach
authors.affiliation: Department of Cardiology, Division of Clinical Electrophysiology, JW Goethe University, Frankfurt, Germany.
authors.forename: Mate
authors.initials: M
authors.lastname: Vamos
authors.affiliation: Department of Cardiology, Division of Clinical Electrophysiology, JW Goethe University, Frankfurt, Germany.
authors.forename: Stefan H
authors.initials: SH
authors.lastname: Hohnloser
keywords: Atrial fibrillation; cardioversion; direct oral anticoagulants; stroke prevention
references.citation: Circulation. 2011 Jan 18;123(2):131-6
references.pmid: 21200007
references.citation: J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76
references.pmid: 24685669
references.citation: JAMA. 1962 Nov 3;182:548-55
references.pmid: 13931298
references.citation: Am J Cardiol. 1969 Feb;23(2):208-16
references.pmid: 4180019
references.citation: Curr Opin Neurol. 2012 Feb;25(1):27-35
references.pmid: 22143201
references.citation: Circulation. 2006 Jul 11;114(2):119-25
references.pmid: 16818816
references.citation: N Engl J Med. 1963 Aug 15;269:325-31
references.pmid: 13931297
references.citation: Stroke. 1996 Oct;27(10):1760-4
references.pmid: 8841325
references.citation: N Engl J Med. 2012 Jan 12;366(2):120-9
references.pmid: 22236222
references.citation: N Engl J Med. 2009 Sep 17;361(12):1139-51
references.pmid: 19717844
references.citation: N Engl J Med. 1956 Apr 19;254(16):727-32
references.pmid: 13309666
references.citation: Lancet. 2014 Mar 15;383(9921):955-62
references.pmid: 24315724
references.citation: J Am Coll Cardiol. 2013 May 14;61(19):1998-2006
references.pmid: 23500298
references.citation: Eur Heart J. 2013 Jul;34(27):2094-106
references.pmid: 23625209
references.citation: Eur Heart J. 2012 Nov;33(21):2719-47
references.pmid: 22922413
references.citation: N Engl J Med. 2001 May 10;344(19):1411-20
references.pmid: 11346805
references.citation: Eur Heart J. 2014 Dec 14;35(47):3346-55
references.pmid: 25182247
references.citation: N Engl J Med. 2011 Sep 15;365(11):981-92
references.pmid: 21870978
references.citation: Circulation. 2006 Aug 15;114(7):e257-354
references.pmid: 16908781
references.citation: Am J Cardiol. 2001 Dec 15;88(12):1428-31, A8
references.pmid: 11741568
references.citation: N Engl J Med. 2011 Sep 8;365(10):883-91
references.pmid: 21830957
references.citation: J Am Coll Cardiol. 2014 Mar 25;63(11):1082-7
references.pmid: 24211508